CI

At a glance

ClinicalIndex Comparison Record
Phase 4Not Yet Recruiting· 60 target
Drug / intervention
Dexmedetomidine-esketamine combination +1 moredrug
Likely dose
Dexmedetomidine-esketamine combination 0.4 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07610343
NCT07610343Phase 4Not Yet Recruiting

Impact of Intranasal Dexmedetomidine-esketamine on Sleep Quality and Cognitive Function in Older Adults With Mild-to-moderate Cognitive Impairment: a Randomized, Double-blind, and Placebo-controlled Trial

Peking University First Hospital·interventional·Posted May 27, 2026·Updated Jun 1, 2026

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine-esketamine combination and Placebo for Older Adults and 4 related conditions. Not yet recruiting, targeting 60 participants across 1 site.

Detailed Summary

Patients with cognitive decline are frequently comorbid with sleep disorders which may in turn aggravate cognitive decline. Sedative dose dexmedetomidine improved sleep quality but incresed bradycardia and hypotension; low dose dexmedetomidine produce less side effects, but the sleep promoting effects are relatively weak. Low dose esketamine also has sleep-promoting effects but may produce neuropsychiatric side effects. Both dexmedetomidine and esketamine are approved for intranasal administration. We suppose that intranasal administration of dexmedetomidine-esketamine combination may improve sleep quality and therefore cognitive function in older ptients with Alzheimer's disease cognitive impairment and sleep disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4Not Yet Recruiting
20272028
First PostedMay 27, 2026
Enrollment StartJun 1, 2026
Primary CompletionNov 1, 2027
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 1 month agoPrimary completion in 1.3 years

Interventions

Dexmedetomidine-esketamine combinationdrug

The dosage will be calculated based on body weight (approximately 0.4 μg/kg of dexmedetomidine and 0.2 mg/kg of esketamine). The mixture of study drugs will be administered via a nasal spray device, alternating between the two nostrils every 5 minutes, until the target dose is reached. The combination will be administered twice a week for 4 consecutive weeks (8 sessions in total).

Placebodrug

The dosage (volume) will be calculated based on body weight in the same way as that in the intervention group. The placebo (normal saline) will be administered via a nasal spray device, alternating between the two nostrils every 5 minutes, until the target dose is reached. The placebo will be administered twice a week for 4 consecutive weeks (8 sessions in total).